Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | CDK9 | P50750 | 10/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27035372 | 1.00 | PARP1 (0.43) | PARP1CDK9CDK1CCNT1HTR6 | |
| SCHEMBL27059733 | 1.00 | PARP1 (0.43) | PARP1CDK9CDK1CCNT1HTR6 | |
| Hydrochloric Acid SCHEMBL27035360 | 0.99 | PARP1 (0.42) | PARP1CDK9CDK1CCNT1HTR6 | |
| SCHEMBL24683422 | 0.90 | PARP1 (0.41) | PARP1CDK9CDK1CCNT1HTR6 | |
| SCHEMBL29845257 | 0.90 | PARP1 (0.41) | PARP1CDK9CDK1CCNT1HTR6 | |
| SCHEMBL30769850 | 0.82 | PARP1 (0.41) | PARP1 | |
| SCHEMBL30769931 | 0.82 | PARP1 (0.41) | PARP1CDK9CCNT1HTR6HTR1A | |
| SCHEMBL27035288 | 0.82 | PARP1 (0.41) | PARP1CDK9CCNT1HTR6HTR1A | |
| SCHEMBL27035497 | 0.82 | PARP1 (0.45) | PARP1 | |
| SCHEMBL29845331 | 0.81 | CDK9 (0.40) | PARP1CDK9CDK1CCNT1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | PARP1 2161/4885CDK9 419/4885CDK1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.